Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03675308 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
A Phase 3 study of Psoriatic Arthritis, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 964
- Enrollment target
- 20
- Study locations
NCT03675308 is a Phase 3 study of Psoriatic Arthritis that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 964 participants, above the 833-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT03675308, a Phase 3 study of Psoriatic Arthritis, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 964 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Risankizumab
Study Locations (20)
Florida
- Arthritis & Rheumatic Disease Specialties /ID# 210802 - Aventura
- Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 211099 - Boca Raton
- SIMED Health, LLC /ID# 207461 - Gainesville
- Sweet Hope Research Specialty Inc /ID# 209393 - Hialeah
- Jacksonville Center for Clinical Research /ID# 209876 - Jacksonville
- Rheum Assoc of Central FL /ID# 201622 - Orlando
- HMD Research LLC /ID# 208427 - Orlando
Arizona
- Sun Valley Arthritis Center Ltd. /ID# 200270 - Peoria
- AZ Arthritis and Rheumotology Research, PLLC /ID# 209873 - Phoenix
- Arizona Arthritis & Rheumatology Research, PLLC /ID# 209875 - Tucson
- Southern Arizona VA Health Care System /ID# 209247 - Tucson
California
- Valerius Medical Group & Research Center /ID# 207428 - Los Alamitos
- Rheumatology Center of San Diego /ID# 201642 - San Diego
- Inland Rheum Clin Trials Inc. /ID# 201641 - Upland
- Medvin Clinical Research /ID# 211127 - Whittier
Connecticut
- New England Research Associates, LLC /ID# 207237 - Bridgeport
- Danbury Clinical Research, LLC /ID# 209517 - Danbury
- Arthritis & Osteoporosis Center /ID# 207236 - Hamden
Alabama
- Pinnacle Research Group /ID# 167955 - Anniston
Arkansas
- Arthritis and Rheumatism Associates /ID# 209882 - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 964 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2026-09-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03675308
The ClinicalTrials.gov registry entry for NCT03675308 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 964 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 833-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (16% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03675308 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT03675308 about?
NCT03675308 is a clinical study titled "A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy". The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
What is the current status of trial NCT03675308?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 964 participants. The study started on 2019-03-25. Estimated completion is 2026-09-28.
What conditions does trial NCT03675308 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT03675308?
The interventions under investigation include: Placebo (BIOLOGICAL), Risankizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03675308?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03675308 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.